Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients.
- Trial name
- NCT02303327
- Testing
- EBRT + HDR brachytherapy boost, Hypofractionated Dose Escalation Radiotherapy, Androgen deprivation therapy
- Where
- 12 sites in Canada
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Prostate Cancer
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
The purpose of this study is to compare the effects on prostate cancer using radiation therapy with or without chemotherapy.
- Trial name
- NCT01603420
- Testing
- Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Proton Collaborative Group
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00376792
- Testing
- docetaxel, active surveillance, adjuvant therapy
- Where
- 8 sites in Denmark, Finland and 3 more
- Volunteers
- 396 people
- Sponsor
- Scandinavian Prostate Cancer Group
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Prostatic Neoplasms
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
The purpose of this study is to assess the relative efficacy and toxicity of combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA.
- Trial name
- NCT00450008
- Testing
- GM-CSF, thalidomide, docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma
A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer
This phase II trial studies the side effects of radiation therapy [hypofractionated proton beam radiation therapy (PBRT) or intensity-modulated radiation therapy (IMRT)] for the treatment of prostate cancer that has come back…
- Conditions
- Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT04190446
- Testing
- Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mayo Clinic
Prostate Cancer
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or…
- Trial name
- NCT00005096
- Testing
- docetaxel
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
- Trial name
- NCT03412396
- Testing
- Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Bleeding
Bleeding After Robot-assisted Radical Prostatectomy: a Respective Study
Nowadays robot-assisted radical prostatectomy (RARP) has become the standard surgical treatment for localised prostate cancer. The robotic approach has been proven superior to open retropubic prostatectomy (ORP) in terms of…
- Conditions
- Prostate Cancer, Bleeding, Prostate Adenocarcinoma
- Trial name
- UROBLOOD01 (NCT06299046)
- Testing
- robot-assisted radical prostatectomy
- Where
- Italy
- Volunteers
- 194 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Prostate Cancer
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
This clinical study will evaluate the role of combination therapy of Provenge followed by docetaxel for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793219
- Testing
- Sipuleucel-T, Docetaxel
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
Prostate Cancer
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004001
- Testing
- docetaxel, estramustine, mitoxantrone
- Where
- 16 sites in United States
- Volunteers
- 770 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer, Adenocarcinoma of the Prostate
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
MAGIC-8 is a two-arm, multicenter, phase 1b/2 study to assess the efficacy of immunotherapy with either Nivolumab (anti-PD-1) or Nivolumab plus BMS-986253 combined with ADT using Degarelix (LHRH antagonist) for men with…
- Trial name
- NCT03689699
- Testing
- Nivolumab, Degarelix, BMS-986253
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Mark Stein
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Metastatic Prostate Adenocarcinoma
Evaluation of PSMA Antagonist Produced by Two Different Methods
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
- Trial name
- NCT04685811
- Testing
- 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients
This is a prospective phase II study of peri-operative docetaxel plus laparoscopic radical prostatectomy in patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate and a risk of relapse after radical…
- Trial name
- NCT00127088
- Testing
- docetaxel, laparoscopic radical prostatectomy
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer, Prostate Adenocarcinoma
Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer
Recent guidelines now recommend multi parametric magnetic resonance imaging prior to biopsy for all men as an integral part of improved diagnosis of clinical significant prostate cancer.
- Trial name
- NCT06029088
- Where
- Turkey (Türkiye)
- Volunteers
- 616 people
- Sponsor
- Ankara Etlik City Hospital